Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3mc Syndrome 2 C0796279
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3mc Syndrome 2 for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3mc Syndrome 2 C0796279
A rare genetic condition similar to other 3MC types, affecting multiple systems with facial, developmental, and growth manifestations. Treatment focuses on symptom management.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3mc Syndrome 2 C0796279
0-0
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3mc Syndrome 2 C0796279
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3mc Syndrome 2 C0796279
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3mc Syndrome 2 C0796279
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3mc Syndrome 2 C0796279
congenital
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3mc Syndrome 2 C0796279
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3mc-syndrome-2-C0796279 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3mc Syndrome 2 C0796279 | Discriminating power |
|---|---|---|---|
| Neurologic features | Developmental delay, seizures, and movement difficulty are described. | Developmental effects may occur; seizures are not established here. | High |
| Physical pattern | Primarily a metabolic nervous-system disorder. | Facial, growth, and multisystem congenital features are described. | High |
| Onset | Early childhood onset, within 0–5 years. | Congenital onset, present at birth. | Moderate |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Early seizures with developmental delay
This pattern fits the described serine-synthesis disorder better.
Moderate
Suspected impaired serine production
Amino-acid testing is relevant, but no cutoff is supplied.
High
Metabolic therapy is being considered
Source management includes serine supplementation and anticonvulsants as needed.
Moderate
Choose 3mc Syndrome 2 C0796279 when
Congenital facial and growth findings
These are the described core features of 3MC syndrome 2.
Moderate
No serine-metabolism clue
A congenital genetic evaluation is more appropriate than assuming a metabolic diagnosis.
Moderate
Supportive care is the main plan
Source management is symptom-focused rather than serine replacement.
High
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3mc Syndrome 2 C0796279 | Interpretation |
|---|---|---|---|
| Plasma or CSF amino acids | Serine, sometimes glycine, may be low; no cutoff is supplied. | No characteristic serine abnormality is established. | A low result supports but does not alone diagnose the metabolic disorder. |
| Genetic testing | PHGDH-related testing may confirm it when indicated. | Syndrome-specific testing may confirm 3MC syndrome 2. | Genetics can distinguish etiology; test choice needs clinical judgment. |
| Dysmorphology and growth assessment | Not expected to define the condition. | Facial and growth findings are central clinical clues. | Anatomic findings are not themselves a diagnosis. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Chronic neurologic disorder; early serine therapy may help, but individual outcome is not established here.
- Factors
- Seizure burden, developmental impairment, and timing of diagnosis and treatment.
3mc Syndrome 2 C0796279
- Outcome
- Chronic congenital condition managed supportively; described severity is moderate but variable.
- Factors
- Growth, facial or structural needs, developmental course, and supportive care.
Time frame: Lifelong; metabolic onset is early childhood, while 3MC onset is congenital.
Outcome depends on severity and specialized care. Mortality is not established here.
Complications comparison
| Complication | Presentation |
|---|---|
| Seizures | A described neurologic complication. Not established in the supplied description. Anticonvulsant use should be individualized. |
| Developmental impairment | Developmental delay is described and may be severe. Developmental manifestations may occur with variable severity. Early developmental support may benefit either condition. |
| Growth or structural concerns | Not a defining feature in the source. Growth and facial manifestations may require coordinated care. Complications beyond the source are not established. |
Patient education highlights
- HighDifferent causes
The left condition affects serine production; the right is a congenital genetic syndrome. Neither is communicable.
- HighDiagnosis and treatment
One test or symptom should not establish the diagnosis. Treatment differs and requires specialist guidance.
- MediumMonitoring
Report seizures, growth or feeding concerns, and developmental changes promptly.